Role of dopamine transporter imaging in routine clinical practice
- 26 September 2003
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 18 (12) , 1415-1423
Abstract
Functional imaging of the dopamine transporter (DAT) defines integrity of the dopaminergic system and has its main clinical application in patients with mild, incomplete, or uncertain parkinsonism. Imaging with specific single positron emission computerised tomography ligands for DAT (FP‐CIT, β‐CIT, IPT, TRODAT) provides a marker for presynaptic neuronal degeneration. Striatal uptake correlates with disease severity, in particular bradykinesia and rigidity, and monitoring of progression assists in clinical trials of potential neuroprotective drugs. DAT imaging is abnormal in idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy and does not distinguish between these disorders. Dopamine loss is seen even in the earliest clinical presentations of true parkinsonism; a normal scan suggests an alternative diagnosis such as essential tremor, vascular parkinsonism (unless there is focal basal ganglia infarction), drug‐induced parkinsonism, or psychogenic parkinsonism. Congruence between working clinical diagnosis and DAT imaging increases over time in favour of baseline DAT imaging results. Additional applications are characterising dementia with parkinsonian features (abnormal results in dementia with Lewy bodies, normal in Alzheimer's disease); and differentiating juvenile‐onset Parkinson's disease (abnormal DAT) from dopa‐responsive dystonia (normal DAT). © 2003 Movement Disorder SocietyKeywords
This publication has 67 references indexed in Scilit:
- Presumed rapid eye movement behavior disorder in Machado‐Joseph disease (spinocerebellar ataxia type 3)Movement Disorders, 2002
- [ 123 I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's diseaseJournal of Neural Transmission, 2001
- Effect of treatment withL-dopa/carbidopa orL-selegiline on striatal dopamine transporter SPECT imaging with [123I]?-CITMovement Disorders, 1999
- [ 123 I]β-CIT and SPECT in essential tremor and Parkinson's diseaseJournal of Neural Transmission, 1998
- Dopamine transporter density measured by [123I]β‐CIT single‐photon emission computed tomography is normal in dopa‐responsive dystoniaAnnals of Neurology, 1998
- Imaging the pre‐ and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: A SPECT STUDY Using [123I] epidepride and [123I] β‐CITMovement Disorders, 1998
- [123I]β‐CIT single‐photon emission tomography in DOPA‐responsive dystoniaMovement Disorders, 1997
- Brain perfusion scintigraphy with99mTc-HMPAO or99mTc-ECD and123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's diseaseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study.Journal of Neurology, Neurosurgery & Psychiatry, 1997